The numbers tell one story: 12,000 Swiss patients, CHF 2.2 million in fresh capital, a cloud platform built for one of Europe's most privacy-conscious markets. But Agora Care's real bet is simpler—that Americans, like the Swiss before them, want ownership of their own medical scans without begging hospital IT departments for access.
In July 2024, the Geneva-based company closed a seed round worth roughly $2.47 million, structured mostly as convertible loans with participation from existing shareholders and a handful of private investors and family offices who preferred to stay unnamed. The funding came through a mix of CHF 2.0 million in convertibles and direct equity stakes, according to announcements from BioAlps and the Greater Geneva Bern area business cluster. Commercial registry filings later showed those notes converting to shares in staged increments through March 2025—a somewhat meandering path, perhaps, but one that reflects how European growth-stage deals often unfold when founders and backers are still calibrating valuations.
Agora Care didn't name a lead investor, which isn't unusual for rounds of this size in Switzerland's tightly networked medtech scene. The company had already raised $1 million in a June 2021 pre-seed and another CHF 1.8 million in August 2022, the latter earmarked for expanding clinical partnerships within Switzerland. So the July 2024 raise represents less a sudden inflection point than a measured push outward—specifically, toward the United States.
The Proposition: Your Scans, Your Control
Here's what Agora Care offers: a patient-centric cloud platform where individuals aggregate medical imaging from scattered sources—radiology centers, hospitals, orthopedic clinics—into a single account they control. Patients then decide who sees those files, sharing them via secure links rather than waiting for fax machines or CD-ROMs to catch up with the 21st century.
The platform handles DICOM, the imaging standard that's been the backbone of radiology since before the internet learned to stream video. It also layers in report visualization tools, including an AI feature that translates dense medical reports into language patients might actually understand. Whether that AI summary proves genuinely useful or just another chatbot novelty remains an open question, but the impulse is clear: demystify the archive.
By the time the seed round closed, Agora Care counted more than 12,000 patients across Switzerland. The company's current website claims north of 13,000 patients and partnerships with over 50 medical centers, though those figures come from Agora Care itself rather than independent registries or government tallies. Still, in a country of fewer than nine million people, crossing the five-figure patient threshold suggests the platform has found early traction beyond Geneva's academic medical corridors.
All data lives on Swiss soil via Exoscale, and the company secured ISO 27001 certification in March 2024. Compliance with Switzerland's revised data protection law—which took effect in September 2023 and tightened rules around consent and cross-border data flows—sits at the center of Agora Care's pitch. In a market where privacy isn't just a regulatory checkbox but a cultural expectation, that posture matters.
Why Now? And Why America?
The timing isn't accidental. Switzerland is midway through a national push toward electronic patient records (EPRs), with inpatient institutions now required to support EPR systems and the federal government steering the architecture toward FHIR standards as part of its DigiSanté roadmap. Agora Care demonstrated an EPR connector at the eHealth Suisse Projectathon in September 2023 and has since plugged into several regional health networks, including Delta Santé's managed-care system and the Centre Assal orthopedic clinic in Geneva.
But the Swiss market has natural limits. Agora Care will use the new capital to mount promotional campaigns and forge strategic partnerships for a US launch, according to statements published by BioAlps and GGBa last summer. The company also plans to roll out online self-registration, letting patients open accounts without first setting foot in a participating radiology center—a shift that could accelerate onboarding if it works, or expose friction points in user experience if it doesn't.
Entering the United States means navigating a medical imaging landscape that's consolidating fast. GE HealthCare's pending acquisition of Intelerad caps a wave of medical imaging exchange deals that began with Intelerad's own purchases of Ambra Health and Life Image in 2021 and 2022. Larger hospital systems and cloud imaging networks already dominate the infrastructure. Agora Care's patient-owned model—where individuals, not institutions, control the central node—could resonate in a US market increasingly focused on interoperability and consumer access. Or it could struggle against the inertia of hospital IT departments that see patient-initiated sharing as a support headache rather than a feature.
The platform's regulatory posture, built for one of the world's strictest data regimes, might prove an asset or a liability. Swiss-style end-to-end encryption and data residency requirements could differentiate Agora Care among privacy-conscious patients. But they could also complicate partnerships with US providers accustomed to looser standards and faster integration timelines.
The Founders and the Board
Agora Care was founded by Prof. Osman Ratib, former chair of radiology and medical informatics at Geneva University Hospitals and the University of Geneva, where he also held faculty positions. Ratib previously served as vice-chair at UCLA and founded the OsiriX Foundation, which developed open-source DICOM viewing software that became an industry standard. Co-founder and CTO Joël Spaltenstein handles the technical build.
In 2021, Jurgi Camblong—CEO and co-founder of SOPHiA GENETICS, the genomics software company that went public on Nasdaq that same year—joined Agora Care's board as chair alongside the pre-seed round. More recent registry filings show a reshuffled board, with Romain Boichat serving as president and Daniel Kerpelmann as vice-president as of mid-2025. Whether Camblong remains involved in an advisory capacity isn't clear from public records, but the reshuffle suggests the company's governance evolved as it prepared for a broader market push.
Agora Care operates out of FONGIT, Geneva's foundation for technological innovation, and counts Tech4Trust among its backers, though neither organization was named as lead on the July 2024 seed round. That's not necessarily a signal—Swiss incubators and early supporters often step back as startups mature and bring in outside capital.
What Comes Next
Agora Care's US gambit will test whether a platform designed for Swiss sensibilities can translate to a market where healthcare delivery is messier, more fragmented, and—arguably—hungrier for patient-empowering tools. The company enters a landscape where regulatory momentum around data interoperability is building but where institutional resistance to change remains formidable.
If Agora Care succeeds, it won't be the first Swiss medtech export to find a second life in America. But it will need to prove that patients, given the tools, actually want to become custodians of their own imaging archives—and that providers are willing to cede that control. For now, the company's advantage lies in a regulatory framework it didn't choose but learned to navigate, built for one of the world's most demanding data regimes and now exported as a competitive edge. Whether that's enough remains the open question.
